X4 Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
X4 Pharmaceuticals, Inc. carries a market capitalization of 374.45M, placing it among publicly traded companies globally. Its enterprise value stands at 87.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 374.45M |
| Enterprise Value | 87.17M |
Share Statistics
X4 Pharmaceuticals, Inc. currently has 94.32M shares outstanding.
| Shares Outstanding | 94.32M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 27.03, and the price-to-book ratio stands at -0.40.
| PE Ratio | N/A |
| PS Ratio | 27.03 |
| PB Ratio | -0.40 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | -2.62 |
| P/OCF Ratio | -2.62 |
Enterprise Valuation
| EV / Sales | 9.67 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
X4 Pharmaceuticals, Inc. maintains a current ratio of 10.18, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.86, indicating elevated leverage, while an interest coverage ratio of -10.98 demonstrates limited ability to service its debt obligations.
| Current Ratio | 10.18 |
| Quick Ratio | 9.88 |
| Debt / Equity | 45.86 |
| Debt / EBITDA | -0.80 |
| Interest Coverage | -10.98 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -49.82 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.42 |
Taxes
| Income Tax | 7,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
X4 Pharmaceuticals, Inc.'s stock has gained approximately 0.25252525% over the past 52 weeks. The 50-day moving average sits at 4.13, while the 200-day moving average is 3.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.25252525% |
| 50-Day Moving Average | 4.13 |
| 200-Day Moving Average | 3.74 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, X4 Pharmaceuticals, Inc. generated 9.01M in revenue and converted that into -99.72M in net income, yielding earnings per share of -1.69. EBITDA reached -96.72M, while operating income came in at -97.75M.
| Revenue | 9.01M |
| Gross Profit | 7.38M |
| Operating Income | -97.75M |
| Pretax Income | -99.71M |
| Net Income | -99.72M |
| EBITDA | -96.72M |
| EBIT | -97.75M |
| Earnings Per Share (EPS) | -1.69 |
Balance Sheet
X4 Pharmaceuticals, Inc. holds 233.72M in cash and equivalents against 77.25M in total debt, resulting in a net debt position of -140.39M. Total book value stands at -614.70M, with working capital of 218.21M providing operational flexibility.
| Cash & Cash Equivalents | 233.72M |
| Total Debt | 77.25M |
| Net Debt | -140.39M |
| Equity (Book Value) | -614.70M |
| Book Value Per Share | -10.42 |
| Working Capital | 218.21M |
Cash Flow
X4 Pharmaceuticals, Inc. produced -92.85M in operating cash flow over the past twelve months.
| Operating Cash Flow | -92.85M |
| Capital Expenditures | N/A |
| Free Cash Flow | -92.85M |
| FCF Per Share | -1.57 |
Margins
X4 Pharmaceuticals, Inc. operates with a gross margin of 81.82, reflecting its pricing power and cost economics. The operating margin of -1,084.38 and net profit margin of -1,106.30 provide insight into operational efficiency.
| Gross Margin | 81.82 |
| Operating Margin | -1,084.38 |
| Pretax Margin | -1,106.22 |
| Profit Margin | -1,106.30 |
| EBITDA Margin | -1,073.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -97.95 |
| FCF Yield | -38.11 |
Stock Splits
X4 Pharmaceuticals, Inc.'s most recent stock split took place on April 28, 2025 with a 30:1 split ratio.
| Last Split Date | 4/28/2025 |
| Split Ratio | 30:1 |
Scores
X4 Pharmaceuticals, Inc. posts an Altman Z-Score of -2.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.31 |